耐药肺结核患者营养状况对早期疗效及药物不良反应的影响及风险评分模型构建OA
Impact of nutritional status on early efficacy and adverse drug reactions in patients with drug-resistant pulmonary tuberculosis and construction of a risk scoring model
目的:探讨营养状况对耐药肺结核患者早期疗效及药物不良反应的影响,并构建简化风险评分模型以辅助临床评估.方法:回顾性分析2023年1月1日至2025年1月1日安徽省胸科医院收治的耐药肺结核患者临床资料.采用多因素logistic回归分析2个月末痰菌阴转及药物不良反应的影响因素,并在此基础上筛选独立影响因素构建简化风险评分模型.结果:本研究共纳入276例患者,2个月末痰菌阴转率为75.4%(208/276),多因素 logistic 回归分析显示,体质量指数(body mass index,BMI)≥ 18.5 kg/m2(OR=3.043,95%CI:1.475~6.277)、血清白蛋白≥35 g/L(OR=3.610,95%CI:1.821~7.155)及血红蛋白≥ 90 g/L(OR=4.464,95%CI:1.103~18.068)与2个月末痰菌阴转呈独立正相关,提示上述指标达标者更易实现早期阴转;营养风险筛查2002(nutritional risk screening 2002,NRS 2002)评分≥3 分(OR=0.376,95%CI:0.175~0.808)与痰菌阴转呈独立负相关,提示存在营养风险者更不易实现阴转.在不良反应方面,肝功能损伤中,血清白蛋白≥35 g/L为保护因素(OR=0.286,95%CI:0.166~0.494),NRS 2002 评分≥ 3 分(OR=2.871,95%CI:1.470~5.608)为危险因素;骨髓抑制中,NRS 2002评分≥3分为危险因素(OR=2.422,95%CI:1.312~4.472),CD4+T细胞计数≥410个/μl(OR=0.218,95%CI:0.081~0.584)及血清白蛋白≥35 g/L(OR=0.550,95%CI:0.304~0.993)为保护因素.基于BMI、血清白蛋白、血红蛋白及NRS 2002评分构建的简化风险评分模型显示,随着风险评分增加,患者痰菌未阴转率、肝功能损伤发生率及骨髓抑制发生率均呈逐渐升高趋势(x2趋势值分别为48.733、21.396和11.272,P值均<0.001).结论:营养状况是影响耐药肺结核患者早期疗效及药物不良反应的重要因素.基于BMI、血清白蛋白、血红蛋白及NRS 2002评分构建的简化风险评分模型临床价值良好,可用于早期风险识别并指导个体化营养干预与不良反应监测.
Objective:To investigate the impact of nutritional status on early efficacy and adverse drug reactions in patients with drug-resistant pulmonary tuberculosis(DR-PTB),and to construct a simplified risk scoring model to assist clinical assessment.Methods:A retrospective analysis was conducted on clinical data of patients with DR-PTB admitted to Anhui Chest Hospital from January 1,2023 to January 1,2025.Multivariate logistic regression was used to identify factors influencing sputum culture conversion at the end of the second month of treatment and adverse drug reactions(ADRs).Independent influencing factors were then selected to construct a simplified risk scoring model.Results:A total of 276 patients were enrolled,with a 2-month sputum conversion rate of 75.4%(208/276).Multivariate logistic regression analysis showed that body mass index(BMI)≥18.5 kg/m2(OR=3.043,95%CI:1.475-6.277),serum albumin ≥35 g/L(OR=3.610,95%CI:1.821-7.155),and hemoglobin≥90 g/L(OR=4.464,95%CI:1.103-18.068)were independently positively associated with 2-month sputum conversion,indicating that patients meeting these criteria were more likely to achieve early conversion.In contrast,a Nutritional Risk Screening 2002(NRS 2002)score ≥3(OR=0.376,95%CI:0.175-0.808)was independently negatively associated with conversion,suggesting that patients with nutritional risk were less likely to achieve conversion.In terms of ADRs,for liver dysfunction,serum albumin ≥35 g/L was a protective factor(OR=0.286,95%CI:0.166-0.494),while an NRS 2002 score of ≥3 was a risk factor(OR=2.871,95%CI:1.470-5.608);For bone marrow suppression,an NRS 2002 score of ≥3 was a risk factor(OR=2.422,95%CI:1.312-4.472),a CD4+T-cell count ≥410 cells/μl(OR=0.218,95%CI:0.081-0.584,P=0.002)and serum albumin ≥ 35 g/L(OR=0.550,95%CI:0.304-0.993)were protective factors.A simplified risk scoring model based on BMI,serum albumin,hemoglobin,and the NRS 2002 score showed that as the risk score increased,the rate of patients failing to achieve sputum culture conversion(x2trend=48.733),the incidence of liver dysfunction(x2trend=21.396),and the incidence of bone marrow suppression(x2trend=11.272)all showed a gradual upward trend(all P-values<0.001).Conclusion:Nutritional status plays an important role in early efficacy and adverse drug reactions in patients with DR-PTB.The simplified risk scoring model based on BMI,serum albumin,hemoglobin,and NRS 2002 score has good clinical applicability and can be used for early risk identification,guiding individualized nutritional interventions and ADRs monitoring.
黄鹏飞;肖雨;熊延军;梁雅雪;王华;赵大海
安徽医科大学第二附属医院呼吸内科,合肥 230000||安徽省胸科医院结核八科,合肥 230000安徽医科大学第二附属医院呼吸内科,合肥 230000||安徽省胸科医院结核八科,合肥 230000安徽省胸科医院结核八科,合肥 230000安徽省胸科医院结核八科,合肥 230000安徽省胸科医院结核八科,合肥 230000安徽医科大学第二附属医院呼吸内科,合肥 230000||安徽省胸科医院结核八科,合肥 230000
医药卫生
结核抗药性营养状况治疗结果药物副反应模型,统计学
TuberculosisDrug resistanceNutritional statusTreatment outcomeAdverse drug reactionModels,statistical
《中国防痨杂志》 2026 (10)
1561-1570,10
国家科技重大专项课题耐药结核病创新治疗药物研发子课题(2025ZD1802404)安徽省卫生健康科研项目(AHWJ2024Aa30419) Sub-project of the National Science and Technology Major Project:"Research and Development of Innovative Therapeutic Drugs for Drug-Resistant Tuberculosis"(2025ZD1802404)Anhui Provincial Health Research Project(AHWJ2024Aa30419)
评论